EP
TARS icon

Essential Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

Essential Partners’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.59K Hold
33
– – ﹤0.01% 1820
2026
Q2 		$2.08K Buy
33
+7
+27% +$447 ﹤0.01% 1956
2026
Q1 		$1.82K Hold
26
– – ﹤0.01% 2046
2025
Q4 		$2.13K Hold
26
– – ﹤0.01% 1776
2025
Q3 		$1.54K Buy
26
+23
+767% +$1.13K ﹤0.01% 1880
2025
Q2 		$122 Buy
+3
New +$135 ﹤0.01% 2039

Other funds holding TARS

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Valeo Financial Advisors
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
West Wealth Group
West Wealth Group Irvine, California $645M AUM 17.37% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Essential Partners's TARS Position: Q3 2026 in Review

Essential Partners held its Tarsus Pharmaceuticals (TARS) position steady in Q3 2026 at 33 shares worth $2.59K. The position accounts for ﹤0.01% of the portfolio, ranked #1820.

Essential Partners first reported a position in TARS in Q2 2025 and has held it in 6 quarters since. 15 funds tracked by Wall St. Rank hold TARS as of Q3 2026.

  • Essential Partners held 33 shares of Tarsus Pharmaceuticals worth $2.59K as of Q3 2026.
  • Essential Partners left its Tarsus Pharmaceuticals share count unchanged in Q3 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #1820 holding.
  • Essential Partners first reported a position in Tarsus Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • 15 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.